We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
+$6.44M
Cap. Flow
-$803K
Cap. Flow %
-0.33%
Top 10 Hldgs %
7.68%
Holding
410
New
55
Increased
156
Reduced
186
Closed
11

Top Buys

Rank Stock Value
1
BKCC
BlackRock Capital Investment Corporation
BKCC
+$673K
2
ZLAB icon
Zai Lab
ZLAB
+$472K
3
SCM icon
Stellus Capital Investment Corp
SCM
+$422K
4
DRD
DRDGold
DRD
+$415K
5
OXLC
Oxford Lane Capital
OXLC
+$359K

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$1.16M
2
RUBY
Rubius Therapeutics, Inc
RUBY
+$664K
3
BNTX icon
BioNTech
BNTX
+$663K
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$645K
5
PRTA icon
Prothena Corp
PRTA
+$590K

Sector Composition

Rank Sector Weight
1 Healthcare 27.38%
2 Real Estate 18.81%
3 Energy 13.29%
4 Materials 10.7%
5 Utilities 10.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHD
151
DELISTED
Pioneer Floating Rate Fund
PHD
$499K 0.21%
41,845
+12,996
+45% +$148K
UTHR icon
152
United Therapeutics
UTHR
$26.3B
$499K 0.21%
2,779
-1,597
-36% -$304K
ONC
153
BeOne Medicines Ltd
ONC
$33.8B
$497K 0.2%
1,448
-1,291
-47% -$428K
RIGL icon
154
Rigel Pharmaceuticals
RIGL
$680M
$496K 0.2%
11,426
+2,229
+24% +$84.2K
NBIX icon
155
Neurocrine Biosciences
NBIX
$17.7B
$488K 0.2%
5,012
-1,680
-25% -$161K
APLS
156
DELISTED
Apellis Pharmaceuticals
APLS
$486K 0.2%
7,693
+1,932
+34% +$99.7K
BCRX icon
157
BioCryst Pharmaceuticals
BCRX
$2.37B
$485K 0.2%
30,669
-4,662
-13% -$63.3K
NKTR icon
158
Nektar Therapeutics
NKTR
$2.39B
$485K 0.2%
1,883
-482
-20% -$133K
RDUS
159
DELISTED
Radius Health, Inc.
RDUS
$485K 0.2%
26,615
-15,921
-37% -$317K
BHVN
160
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$483K 0.2%
4,973
-2,220
-31% -$180K
PTCT icon
161
PTC Therapeutics
PTCT
$6.37B
$481K 0.2%
11,368
+1,892
+20% +$81.1K
XLRN
162
DELISTED
Acceleron Pharma
XLRN
$478K 0.2%
3,810
-1,000
-21% -$126K
OMER icon
163
Omeros
OMER
$709M
$477K 0.2%
32,130
-9,070
-22% -$152K
ITCI
164
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$477K 0.2%
11,679
-13,085
-53% -$484K
BLUE
165
DELISTED
bluebird bio
BLUE
$476K 0.2%
1,150
+630
+121% +$250K
INSM icon
166
Insmed
INSM
$23.2B
$474K 0.19%
16,660
+982
+6% +$29.1K
AGIO icon
167
Agios Pharmaceuticals
AGIO
$2.16B
$472K 0.19%
8,573
-9,755
-53% -$546K
TVTX icon
168
Travere Therapeutics
TVTX
$5.33B
$471K 0.19%
32,254
+8,347
+35% +$165K
EPZM
169
DELISTED
Epizyme, Inc
EPZM
$471K 0.19%
56,674
+8,726
+18% +$73.6K
VVR icon
170
Invesco Senior Income Trust
VVR
$456M
$469K 0.19%
105,079
+32,846
+45% +$140K
BGT icon
171
BlackRock Floating Rate Income Trust
BGT
$322M
$468K 0.19%
36,418
+11,218
+45% +$142K
ICPT
172
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$466K 0.19%
23,353
+3,978
+21% +$78.9K
YMAB
173
DELISTED
Y-mAbs Therapeutics
YMAB
$464K 0.19%
13,728
+1,735
+14% +$55.7K
EFR
174
Eaton Vance Senior Floating-Rate Fund
EFR
$311M
$463K 0.19%
32,748
+8,419
+35% +$118K
RARE icon
175
Ultragenyx Pharmaceutical
RARE
$2.65B
$463K 0.19%
4,853
+766
+19% +$79.8K
5 6
7
8 9

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2021 Portfolio in Review

As of Q2 2021, Virtus ETF Advisers held 410 positions worth $243M, up 2.7% from $237M the previous quarter. Its ten largest holdings account for 7.7% of the portfolio.

Virtus ETF Advisers's Q2 2021 filing shows 55 new, 156 increased, 186 reduced and 11 closed positions. Its largest new stake was Zai Lab: 2,937 shares worth $520K. The largest sale was Amyris Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 30% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q2 2021 buy was Zai Lab: 2,937 shares worth $520K.
  • Virtus ETF Advisers added most to BlackRock Capital Investment Corporation in Q2 2021, an estimated $673K increase.
  • Virtus ETF Advisers's biggest Q2 2021 reduction was Amyris Inc., cutting an estimated $1.16M.
  • Virtus ETF Advisers fully exited Five Prime Therapeutics, Inc. in Q2 2021, selling an estimated $645K.
  • Virtus ETF Advisers's ten largest holdings make up 7.7% of its $243M portfolio in Q2 2021.
  • Virtus ETF Advisers opened 55 new positions and closed 11 in Q2 2021.
  • Virtus ETF Advisers's portfolio value rose 2.7% quarter-over-quarter to $243M.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.